Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
Diabetes/Metabolism Research and Reviews · 2024-09 · 40 (6)
DOI: 10.1002/dmrr.3843 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 23.09.2024. Verfasst von Hee-Ju Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Biomarkers, Bone Density, Bone Remodeling, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) may promote bone formation, but conversely, they could also weaken bones due to the reduction in mechanical load associated with weight loss. However, the clinical effects in humans have not been clearly demonstrated. This meta‐analysis aimed to evaluate whether GLP‐1RAs affect BMD and bone turnover markers. Material and Methods PubMed, Embase, and Scopus were searched on June 13, 2024. The eligibility criteria were: (1) human studies, (2) receiving a GLP‐1RA for more than 4 weeks, (3) an untreated control group or a placebo group, (4) reporting of at least one BMD or bone turnover marker, and (5) an RCT design. The risk of bias was assessed using the Cochrane risk of bias 2 tool. Fixed‐ or random‐effects meta‐analysis was performed according to heterogeneity.
Results
Seven studies were included in the meta‐analysis. GLP‐1RAs did not significantly change BMD in the femoral neck (mean difference [MD], 0.01 g/cm 2 ; 95% CI, −0.01–0.04 g/cm 2 ), in the total hip (MD, −0.01 g/cm 2 ; 95% CI, −0.02–0.01 g/cm 2 ), and in the lumbar spine (MD, 0 g/cm 2 ; 95% CI, −0.02–0.02 g/cm 2 ). C‐terminal telopeptide of type 1 collagen (CTX), a bone resorption marker, significantly increased after GLP‐1RA treatment (MD, 0.04 μg/L; 95% CI, 0.01–0.07 μg/L). GLP‐1RAs did not significantly change bone formation markers such as procollagen type 1 N‐terminal propeptide, bone‐specific alkaline phosphatase, osteocalcin.
Conclusions
GLP‐1RA did not affect BMD and bone formation markers. However, GLP‐1RAs led to a significant increase in CTX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.
- Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
- School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.
ORCID-Profile: Myeong Gyu Kim
Zitieren
APA
Kim, H. J., Choi, S. A., Gu, M. S., Ko, S. Y., Kwon, J. H., Han, J. Y., Kim, J. H., & Kim, M. G. (2024). Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis. Diabetes/Metabolism Research and Reviews, 40(6). https://doi.org/10.1002/dmrr.3843
Vancouver
Kim HJ, Choi SA, Gu MS, Ko SY, Kwon JH, Han JY, et al. Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis. Diabetes/Metabolism Research and Reviews. 2024;40(6). doi:10.1002/dmrr.3843
BibTeX
@article{Kim2024,
author = {Kim, Hee-Ju and Choi, Seo-A and Gu, Min-Sun and Ko, Seo-Yeong and Kwon, Jae-Hee and Han, Ja-Young and Kim, Jae Hyun and Kim, Myeong Gyu},
title = {Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2024},
volume = {40},
number = {6},
doi = {10.1002/dmrr.3843}
}
EUVIMED